Emerging treatment strategies for glioblastoma multiforme

Glioblastoma multiforme (GBM) is the deadliest form of brain tumor with a more than 90% 5‐year mortality. GBM has a paltry median survival of 12.6 months attributed to the unique treatment limitations such as the high average age of onset, tumor location, and poor current understandings of the tumor...

Full description

Saved in:
Bibliographic Details
Published in:EMBO molecular medicine 2014-11, Vol.6 (11), p.1359-1370
Main Authors: Carlsson, Steven K, Brothers, Shaun P, Wahlestedt, Claes
Format: Article
Language:English
Subjects:
Biomarkers
Biomedical Research - trends
Brain cancer
brain imaging
Brain Neoplasms - diagnosis
Brain Neoplasms - therapy
Brain tumors
cancer stem cells
DNA methylation
EMBO03
EMBO27
Epigenetics
Glioblastoma
Glioblastoma - diagnosis
Glioblastoma - therapy
Glioblastoma multiforme
glioblastoma multiforme (GBM)
Humans
Immunotherapy - methods
Monoclonal antibodies
Neuroimaging
NMR
Nuclear magnetic resonance
Radiation therapy
Review
Stem cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma multiforme (GBM) is the deadliest form of brain tumor with a more than 90% 5‐year mortality. GBM has a paltry median survival of 12.6 months attributed to the unique treatment limitations such as the high average age of onset, tumor location, and poor current understandings of the tumor pathophysiology. The resection techniques, chemotherapic strategies, and radiation therapy currently used to treat GBM have slowly evolved, but the improvements have not translated to marked increases in patient survival. Here, we will discuss the recent progress in our understanding of GBM pathophysiology, and the diagnostic techniques and treatment options. The discussion will include biomarkers, tumor imaging, novel therapies such as monoclonal antibodies and small‐molecule inhibitors, and the heterogeneity resulting from the GBM cancer stem cell population. Graphical Abstract A comprehensive overview and discussion of our current understanding of glioblastoma multiforme (GBM) pathophysiology and heterogeneity, diagnostic techniques and treatment options, including novel therapies such as monoclonal antibodies and small‐molecule inhibitors.
ISSN:1757-4676
1757-4684
DOI:10.15252/emmm.201302627